Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

Metastatic dissemination occurs very early in the malignant progression of a cancer but the
clinical manifestation of metastases often takes years. In recent decades, 5-year survival of …

Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

The success of targeted therapies and immunotherapies has created optimism that cancers
may be curable. However, not all patients respond, drug resistance is common and many …

Recent advances in targeted therapy and immunotherapy have once again raised the hope
that a cure might be within reach for many cancer types. Yet, most late-stage cancers are …

Cancer cells disseminate and seed in distant organs, where they can remain dormant for
many years before forming clinically detectable metastases. Here we studied how …

Immunotherapy is a promising treatment for triple-negative breast cancer (TNBC), but
patients relapse, highlighting the need to understand the mechanisms of resistance. We …

Cancer metastasis is no longer viewed as a linear cascade of events but rather as a series
of concurrent, partially overlap** processes, as successfully metastasizing cells assume …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Cancer cell dissemination during very early stages of breast cancer proceeds through poorly
understood mechanisms. Here we show, in a mouse model of HER2+ breast cancer, that a …